Business
Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board
MADISON, Wis., July 14, 2025--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies.
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":8364,"height":2328,"url":"https://media.zenfs.com/en/business-wire.com/5cf12bfd6f620f63fbce25a1aa277d40"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kEXz0eec19zK8HGrfaK1.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5cf12bfd6f620f63fbce25a1aa277d40","width":960,"height":267},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TAeQawE4CPAXfcNG1ld4Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Njg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5cf12bfd6f620f63fbce25a1aa277d40","width":1200,"height":334}},"lazy":false},{"type":"text","content":"MADISON, Wis., July 14, 2025--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies.","length":425,"tagName":"p"},{"type":"text","content":"Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a clinical stage biotech company in Pittsburgh, PA. Most recently, he served as Senior Vice President of Human Immunology at Vir Biotechnology. Prior to that, he served as Vice President for Immuno-Oncology Discovery at Bristol-Myers Squibb (BMS), where he led the development of biologics for tumor immunotherapy. During his tenure at BMS and Medarex, Dr. Korman contributed to the development of three approved oncology drugs: ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and relatlimab (anti-LAG-3), as well as their combination, pioneering the use of immune checkpoint blockade in cancer therapy.","length":690,"tagName":"p"},{"type":"text","content":"Dr. Korman earned his PhD in Cellular and Developmental Biology from Harvard University and was a Whitehead Fellow at the Whitehead Institute at the Massachusetts Institute of Technology. He also served as a staff scientist at the Institut Pasteur before transitioning to the biotechnology sector. In addition to his new role on Invenra’s SAB, Dr. Korman is also the founder of Spice Biotechnologie...